Drug Profile

PT 698

Alternative Names: PT-698

Latest Information Update: 28 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Phanes Therapeutics
Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
Mechanism of Action Apelin receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

No development reported Age-related macular degeneration; Diabetic macular oedema; Diabetic retinopathy; Glioblastoma

28 Mar 2026 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (Parenteral)
28 Mar 2026 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in USA (Parenteral)
28 Mar 2026 No recent reports of development identified for preclinical development in Diabetic-retinopathy in USA (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com